Marine-Lenhart Syndrome: Role of Iodinated Contrast Administration, Case Report and A Review of Literature

Mark Chambers DVM, MD\textsuperscript{1,2}, Mazhar Khan MD\textsuperscript{1}, Constance Chen MD\textsuperscript{3}, Steven Secrest CNMT, RT\textsuperscript{1} and Sing-Yung WU, MD, PHD\textsuperscript{1,2}\textsuperscript{*}

1Department of Radiology/Nuclear Medicine, VA Medical Center, Long Beach, California.
2Department of Radiological Sciences, University of California, Irvine, California.
3Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine; VA Long Beach Healthcare System.


ABSTRACT

Objective: High iodine load in vulnerable populations, including the elderly, increases the risk of iodine-induced thyroid dysfunction. We report a case of an elderly patient presented with the Marine-Lenhart syndrome, defined as the coexistence of Graves’ disease and autonomous thyroid nodule(s) that result in biochemical hyperthyroidism. In the present case the thyrotoxic state occurred following a chest CT angiogram.

Methods: Clinical, laboratory, and radiographic data are presented as well as a review of the literature.

Results: A 73 y male has been euthyroid until after a chest CT angiogram. He presented to the endocrine service with thyrotoxic symptoms, including palpitation and weight loss. Suppressed TSH and elevated free T4 were found six weeks after the angiogram with a positive thyroid-stimulating immunoglobulin. A thyroid ultrasound examination revealed a solid nodule in the medial right lobe where a hot nodule was found on I-123 thyroid scan with a highly elevated 24-hour uptake. He received radioiodine therapy after 2 months of treatment of methimazole.

Conclusion: This case demonstrates the occurrence of Marine-Lenhart syndrome in an older man, likely due to exposure to an excess iodine load. As the elderly represent a group at increased risk of iodine-induced thyroid dysfunction, it is advised to monitor serum thyroid function following the administration of iodinated contrast media in older individuals.

Keywords
Hyperthyroidism, Marine-Lenhart Syndrome, Iodinated Contrast, Elderly Patients, Subclinical Hyperthyroidism.

Introduction

The Marine-Lenhart syndrome refers to the coexistence of Graves’ disease and a superimposed autonomous thyroid nodule that result in biochemical hyperthyroidism. Mechanisms underlying this syndrome include somatic constitutively activate mutations in the TSH receptors and the presence of anti-TSH receptor autoantibodies. The present case is an unusual report in an elderly patient of Marine-Lenhart syndrome, and the administration of iodinated contrast may play a role in the mechanism of its onset.

Case Report

A 73-yrs male (as shown in Table, Patient A) has been euthyroid until after a chest CT angiogram on 3/31/2018. He presented to the endocrine service with thyrotoxicosis, including palpitation and weight loss. Suppressed TSH (0.01 mIU/L, reference range, 0.55-0.78 mIU/L and elevated free T4 (3.8 ng/dL, reference range, 0.67-1.52 ng/dL) were found on May 18, six weeks after the angiogram with a positive thyroid-stimulating immunoglobulin (TSI), 458%
(reference range <140%). A thyroid ultrasound examination revealed a 1.8x1.3x2.1 cm solid nodule in the medial right lobe where a hot nodule was found on an I-123 thyroid scan with an elevated 24-hour uptake of 57.5% (reference range, 8 – 35%). He received radioiodine therapy after two months of treatment of methimazole.

The Table shows a summary of the patient’s serum thyroid function tests, in comparison with another similar elder patient with iodinated contrast-induced coexistence of thyrotoxicosis and autonomous nodule with a negative TSI [1]. Figure 1, a thyroid I-123 nuclear scan on 6/27/2018, showed a patchy increased uptake bilaterally and a hot thyroid nodule in the right lower lobe corresponding to a solid nodule on thyroid ultrasound examination. Figure 2 showed a thyroid ultrasound examination on 5/17/2018. The images include the long sagittal (left) and trans-axial (right) images. There is a 1.8 x 1.3 x 2.1 cm predominantly solid nodule in the medial right lower lobe, and a 2.5x1.0x2.2 cm hypoechoic nodule in the posterior right lobe. The left lobe is diffusely nodular. On the ultrasonic examination, 18 months after radioiodine therapy (999 MBq), both nodules became unidentifiable, while the overall thyroid volume reduced to 20% of original size.

**Discussion**

Thyroid-stimulating antibody-positive toxic goiter (Graves’ disease) and toxic nodular goiter both result in biochemical hyperthyroidism, but by different pathophysiologic mechanisms.

<table>
<thead>
<tr>
<th>Patient (age/sex)</th>
<th>Time after CT-Contrast</th>
<th>TSH (.55-4.78 mIU/L)</th>
<th>FT4 (.67-1.52, ng/dL)</th>
<th>TSI Ab (≥140% baseline)</th>
<th>RAIU (4h,3-20% 24h,8-35%)</th>
<th>Thyroid Scan/US (see below)</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. 73/M</td>
<td>1.5 month</td>
<td>0.01</td>
<td>3.8</td>
<td>458%</td>
<td>36% (4h); 57.5% (24h)</td>
<td>Patchy ↑uptake with a hot nodule</td>
<td>RAI therapy after 2 months treatment of MMI</td>
</tr>
<tr>
<td>B. 70/M*</td>
<td>&lt;16 month</td>
<td>0.01</td>
<td>1.9</td>
<td>93%</td>
<td>24.6% (4h); 53.9% (24h)</td>
<td>Diffuse ↑uptake with hot nodule</td>
<td>No therapy, spontaneous recovered 12 months later</td>
</tr>
</tbody>
</table>

* Ref (1)

Table 1: Two cases of iodinated contrast- induced Marine-Lenhart syndrome, the current patient (A): time after a contrast CT, serum thyroid function, serum antibody titers, thyroid imaging studies and treatment in comparison with a similar case (patient B) with negative TSI reported recently [1].

Figure 1: I-123 thyroid scan on 6/27/2018 showed a slightly patchy increased uptake bilaterally (57.5% at 24 h) and a hot thyroid nodule in the right lower lobe corresponding to a solid nodule on thyroid ultrasound examination.

Figure 2: Thyroid ultrasound examination on 5/17/2018. The image is the sagittal (long) and trans-axial images (Upper) There is a 1.8x1.3x2.1 cm predominantly solid nodule in the medial right lower lobe. (Lower) a 2.5x1.0x2.2 cm hypoechoic nodule in posterior lower right lobe.

The original report of Marine-Lenhart syndrome, the coexistence of these two entities, was published over a century ago [2] and reported the concurrent development of both in the same patient has been described in several more recent reports [3-6], including our prior case study [1].

In the present report, we describe a case in which both Graves’ disease and an autonomous thyroid nodule were likely exacerbated simultaneously by exposure to an excess iodine load that occurred...
1.5 months before in a chest angiogram study. This patient was unlike the prior one (patient B in Table) reported recently that was somewhat unusual that the exposure was remote, occurring 22 months before the diagnosis of hyperthyroidism [1]. The other interesting point is the positive TSI antibody found in the present patient compared to the negative titer in the last case [1]. The difference in TSI titer between these two individuals may be correlated with the difference in the clinical course between these two patients. The present patient was treated with radioiodine I-131 after two months of therapy with methimazole while the other patient with negative TSI titer reverted to the euthyroid state spontaneously after refusing recommended treatment [1,7].

Toxic nodular disease (Plummer’s Disease) is often produced by the development of nodular thyroid disease, including the growth of established nodules, new nodule formation, and development of autonomy over time [7,8]. This disease prevails in elderly patients, and is postulated that the autonomous functioning thyrocytes originate more often in the iodine-deficient region over a long period. Mechanisms in the development of thyroid nodules involve cellular mutations. Currently, more than 30 oncogenes may be involved in the development of nodules, e.g., RAS, BRAF, and RET/PTC, etc. [9]. When the mass of mutated cells becomes sufficient and iodine supply is increased, the subject may become thyrotoxic [10]. In fact, it has been suggested that iodine-induced hyperthyroidism may also occur in “latent” Graves’ disease as in the present cases [11,12].

Thyroid nodules associated with Graves’ disease have been reported with the incidence between 13 to 34% (mean 23.5%), most of which are cold nodules in a retrospective review of 1733 patients (13-17). The incidence of Graves’ disease accompanied by a single hot nodule, as shown in our two patients, ranges from 1 to 2.7% and represents a rare form of Marine-Lenhart syndrome [3,4]. Most reported cases among Graves’ disease with hyperfunctioning nodules are multiple.

In the two elderly patients who may have latent Graves’ disease with or without detectable TSI antibody in conjunction with a nodular goiter might be responsible for developing Marine-Lenhart syndrome induced by excess iodine after intravenous administration of radiocontrast media. As shown in the scan (Figure 1), the slightly patchy appearance may be associate with some follicular degeneration in contrast with the homogeneously increased uptake in the remaining thyroid gland outside the hot nodule in a prior report [1], despite the suppressed level of TSH in these cases, are consistent with the underlying Graves’ disease.

A large controlled study found an association between radiocontrast administration and incident hyperthyroidism in the euthyroid patient population [18]. In some susceptible individuals, the elderly with nodular goiter, as in the present case, the use of these iodine-containing substances can result in thyroid dysfunction due to the high iodine load. In certain circumstances, iodine excess can result in adverse thyroidal effects after only a single exposure to an iodine-rich substance, as demonstrated in the present cases [1,19]. Iodine-induced hyperthyroidism (the Jod–Basedow phenomenon) was observed to be more common among patients with endemic goiter treated with iodine supplementation than in individuals without goiter [7,8]. Furthermore, iodine-induced hyperthyroidism in euthyroid patients with nodular goiter in iodine-sufficient areas has also been reported when iodine supplementation is excessive [10].

The use of iodinated contrast agents in diagnostic radiologic studies is a common source of excess iodine exposure in many patients [20]. A single dose of iodinated contrast can contain up to 13,500 μg of free iodine and 15–60 g of bound iodine [18,20]. Following the exposure to an iodinated contrast agent in a CT examination, iodine stores remain elevated and provide a continuous pool for 1 - 2 months [21-23]. In euthyroid, healthy adults without previous thyroid or renal disease, urinary iodine content did not return to baseline in a study with a small number of older participants over 75 days [21] following exposure to the contrast agent. A Turkish study of 101 patients found a small increased risk of subclinical hyperthyroidism (6%) at up to 8 weeks after the iodine exposure [24,25]. A German study of 788 patients who underwent coronary angiography found only two male patients did not belong to a risk group, although older (55 and 68 yrs) developed overt hyperthyroidism in 4 weeks after exposure to contrast media [26]. In the large case-control study in the Boston area found that patients without pre-existing hypothyroidism or hyperthyroidism who received a single iodinated contrast dose had a 2-3-fold increased risk of developing either incident hyperthyroidism (including overt hyperthyroidism) or overt hypothyroidism at a median of 9 months following exposure, compared with patients who did not receive the high iodine load [18]. A similar finding of 1.6 to 2.0 times the odds of developing incident thyroid dysfunction, including hyperthyroidism, was found in a community-based cohort of ambulatory patients [27]. However, in an elderly population (70 – 96 yrs of age), iodine-induced thyrotoxicosis following contrast radiography was found in 7 of 28 cases of hyperthyroidism in a geriatric hospital [21]. This patient’s age distribution is closer to our VA patient population (52.2% of VA-veterans are age 65 or older) in the 2015 Rand study with the source from 2006-2012 analysis [28].

Iodine-induced thyroid dysfunction is a potential consequence in patients with nodular goiters and elderly patients [26]. Undiscovered and untreated hyperthyroidism is a dangerous clinical condition; it may lead to multiple organ involvement and even a life-threatening cardiac event [12,29–32].
hyperthyroidism. This effect may appear 4 to 6 weeks after the IV contrast administration in some of these patients. This can occur after the administration of any iodinated contrast media. It is usually self-limited.” [34]. This guideline appears to have ignored some of the relevant data, especially in the elderly at-risk and critically-ill patients in ICU. This issue may deserve a closer evaluation, especially in the VA elderly population.

Radioiodine and thionamides are both effective treatment for Graves' hyperthyroidism. Radioiodine has been the therapy of choice in the United States, selected by 60 percent of thyroid specialists who responded to a survey in 2011 [35]. Data subsequently have shown that long-term antithyroid drug use is safe [36], and an updated analysis using insurance claims data in the United States suggests that antithyroid drugs are used as initial therapy for 60 percent of patients, while only 33 percent of patients receive radioiodine [37].

Our prior reported case with the co-occurrence of Graves’ disease and a functional nodule did not continue to retain autonomy following the spontaneous remission of the Graves’ disease after the iodine pool had returned to baseline [1]. We are not aware of any case report of iodine-induced as shown in these two cases or spontaneous remission of hyperthyroid state in Marine-Lenhart syndrome, as demonstrated in our prior report [1]. In susceptible patients, especially elderly patients with nodular goiters and prior history of iodine-induced hyperthyroidism should be counseled regarding the risk, as demonstrated in the present patients. Prophylactic treatment with anti-thyroid medication and/or beta-blocker may be considered before exposure to contrast agents even though it may not routinely be recommended because of the side effects of these drugs in the low-risk general patient population. To recognize the self-limiting nature of radio-contrast induced hyperthyroidism, especially in TSI negative patients, is important in order to avoid over-treatment as demonstrated in our prior report [1]. Thus, in iodine-induced hyperthyroidism, thionamides is the preferred treatment as compared with RAI ablative therapy. There is an association of thyroid cancer in patients with Graves’ disease [38,39]. However, an autonomously functioning papillary thyroid cancer in Marine-Lenhart syndrome nodule is rare [40,41].

Conclusion
We present a hyperthyroid patient diagnosed with Marine-Lenhart Syndrome, defined as the coexistent presentation of Graves’ disease and an autonomous thyroid nodule, following administration of an iodinated contrast load.

This case illustrates the mechanism turning on both toxic nodule and under Graves' hyperthyroidism simultaneously by a single switch: the excess supply of iodine. It also demonstrates the importance of monitoring elderly patients, a group at increased risk for developing iodine-induced thyroid dysfunction. Such patients should be closely monitored following the administration of iodinated contrast media, which represents an increasingly common source of excess iodine exposure. The present case also illustrated iodine load may play a role in the mechanism of onset of both Graves’ hyperthyroidism and an autonomous toxic nodule.

Reference
11. Braverman LE, Cooper DS. Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text. 2012; 250.


41. Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26: 1-133.